Omnes Capital's investments

Founded in 2010 and based in Rambouillet, the French start-up Nanomakers has been designing and producing since 2012 patented silicon-based nanopowders which transform the mechanical, chemical or thermal properties of materials. Its disruptive technology has made it possible to triple the energy density of Li-ion batteries anodes, or to lighten and reinforce the mechanical properties of certain materials (metal alloys, elastomers) used in various industrial sectors.

Tilkee was founded by Sylvain Tillon and Timothée Saumet in decembre 2013. The company offers a complete suite of document tracking solutions: Tilkee for Sales, Tilkee for Marketing, Tilkee for Jobs and Tilkee for Events. Tilkee currently employs 24 people and is growing in Europe (Germany, United Kingdom, Spain). Tilkee’s clients include EDF, Orange, Schneider Electric, Credit Agricole and Adecco

ForCity was founded in 2014 and employs over 82 people based in Lille, Lyon, Rennes and Paris.

ForCity provides public authorities and businesses with a simulation tool to help them anticipate such challenges and optimise planning. Their tools enable their users to simulate any and all the scenarios they may want to explore. ForCity is helping to transform the management of services and infrastructures in cities.

ForCity: accredited French Tech prizewinner before its first fundraising initiative.

Founded in 2015, VSORA will introduce innovative DSP IP solutions to accelerate the design of complex integrated circuits, prevalent in the mobile, networking and consumer product markets. It has offices in Velizy-Villacoublay.

 

Based in Paris, Enterome is an innovative theranostics company dedicated to discovering and developing biomarkers to diagnose and treat inflammatory conditions (Crohn’s disease, ulcerative colitis) linked to anomalies in intestinal composition using a unique platform that harnesses the power of the human microbiome. In addition to its inflammatory franchise, the Enterome platform can also be used for a vast range of applications such as monitoring and treating metabolic conditions (fatty liver, obesity, diabetes). 

Themis Bioscience GmbH develops vaccines at the pre-clinical and early clinical stages.
The Vienna-headquartered company specialises in emerging tropical diseases. The first vaccine candidates currently under development target Chikungunya and Dengue fever. Themaxyn®, the innovative platform originally developed at the Pasteur Institute in Paris and protected by a number of patents, represents the vector for all the company’s current vaccine candidates.

 

Offered in SaaS mode to marketing teams looking to adopt a data-driven approach while remaining highly agile, the AB Tasty solution helps e-commerce sites, interactive service providers and media to improve their conversion rate, irrespective of whether their digital presence consists of web sites, mobile sites or native applications. A holder of the French Tech Pass and the BPI Excellence seal of quality, AB Tasty ranks among the most innovative businesses operating in the French web ecosystem.